Who is on it, and how far along Every drug ChEMBL records acting on ROCK1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved2 Belumosudil Belumosudil SponsorSanofi-Aventis ModalitySmall molecule ActionInhibitor Open trials19 Netarsudil Netarsudil SponsorAlcon ModalitySmall molecule ActionInhibitor Open trials12 Phase 33 Fasudil Fasudil SponsorWoolsey Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials5 Ripasudil Ripasudil SponsorKowa Research Institute, Inc. ModalitySmall molecule ActionInhibitor Open trials5 AMA0076 AMA0076 SponsorAmakem, NV ModalityOther ActionInhibitor Open trials0 Phase 23 DE-104 DE-104 SponsorSanten Pharmaceutical ModalityOther ActionInhibitor Open trials0 SAR-407899 free base SAR-407899 free base SponsorSanofi ModalitySmall molecule ActionInhibitor Open trials0 Verosudil Verosudil SponsorAerie Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials0 Phase 12 AT-13148 AT-13148 SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0 Y-39983 Y-39983 SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Rho-associated protein kinase inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 26 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients Netarsudil Phase 4 Recruiting Brett King Sep 29, 2026 Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD Belumosudil Not applicable Recruiting First Affiliated Hospital of Zhejiang University Aug 31, 2026 A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease Belumosudil Phase 3 Recruiting Sanofi Aug 18, 2026 Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants Belumosudil Phase 1 Not yet recruiting Sanofi Jul 24, 2026 Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD) Belumosudil Phase 2 Not yet recruiting Dennis Kim Jun 11, 2026 A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT Belumosudil Phase 2 Recruiting WeiShi May 26, 2026 Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension Netarsudil Phase 4 Recruiting Indiana University May 14, 2026 IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD Belumosudil Phase 1 Not yet recruiting Stanford University Mar 19, 2026 Rocklatan vs Latanoprost Post-DSLT Netarsudil Phase 4 Recruiting Eye Centers of Southeast Texas Mar 12, 2026 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients Netarsudil Phase 4 Recruiting Mayo Clinic Jan 8, 2026 A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer Fasudil Phase 2 Recruiting baotai Liang Nov 26, 2025 Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma Netarsudil Phase 4 Recruiting Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, Oct 7, 2025 A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) Belumosudil Phase 4 Not yet recruiting Sanofi Aug 22, 2025 Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD Belumosudil Phase 1 Recruiting M.D. Anderson Cancer Center Aug 17, 2025 Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues Netarsudil — Not yet recruiting Association for Innovation and Biomedical Research on Light and Image Jul 20, 2025 Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) Netarsudil Phase 4 Not yet recruiting Center for Sight Las Vegas Jul 3, 2025 The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy Netarsudil — Enrolling by invitation University Hospital Dubrava May 14, 2025 A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer Fasudil Phase 2 Recruiting Zhejiang Provincial People's Hospital Mar 24, 2025 Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer Fasudil Phase 2 / Phase 3 Recruiting baotai Liang Mar 6, 2025 Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD) Fasudil Phase 2 Recruiting Helse Stavanger HF Apr 12, 2024 The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery Ripasudil Phase 3 Recruiting Singapore Eye Research Institute Sep 21, 2023 Study to Assess Safety and Tolerability of Multiple Doses of EO2002 Ripasudil Phase 1 Recruiting Asociación para Evitar la Ceguera en México Dec 5, 2022 Descemet Endothelial Thickness Comparison Trial I Ripasudil Phase 3 Active, not recruiting Stanford University Mar 21, 2022 Descemet Endothelial Thickness Comparison Trial II Ripasudil Phase 3 Active, not recruiting Stanford University Mar 11, 2022 Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) Fasudil Phase 2 Active, not recruiting Woolsey Pharmaceuticals Feb 1, 2022 Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy Ripasudil Phase 4 Recruiting Marian Macsai, MD Aug 15, 2017
Show all 26Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2111459 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets